PBYI$5.70
Chart
Performance
Key Stats
AI PBYI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldPuma Biotechnology (PBYI) presents a mixed investment profile. While its core product, NERLYNX, addresses a significant oncology market and the company has demonstrated periods of positive EPS surprises, its recent performance shows volatility. The current valuation metrics are somewhat favorable, but the technical indicators suggest a bearish short-term outlook. Long-term potential depends on pipeline development and market penetration of existing therapies.
Thematic
Puma Biotechnology operates within the biopharmaceutical sector, focusing on oncology. The thematic appeal lies in the ongoing demand for innovative cancer treatments, particularly for HER2-positive breast cancer. However, the company faces intense competition and the evolving landscape of drug development and pricing. The broader trend of personalized medicine and targeted therapies is a positive backdrop, but PBYI's specific market position requires careful consideration.
Fundamental
Puma Biotechnology shows a mixed fundamental picture. While recent earnings have beaten expectations, revenue has seen some decline. The company's valuation metrics, such as P/E ratio, are relatively low, suggesting it might be undervalued based on trailing earnings. However, the absence of dividends and a moderate debt level require attention. The company's financial position indicates a manageable debt-to-equity ratio and positive free cash flow in the most recent year.
Technical
The technical indicators for Puma Biotechnology suggest a bearish short-term outlook. The stock has experienced a significant price decline over the past month and year. Momentum indicators like RSI are in oversold territory, signaling potential for a bounce, but the overall trend, confirmed by moving averages, remains downward. Support levels are being tested, and a break below them could lead to further declines.
| Factor | Score |
|---|---|
| Oncology Market Growth | 70 |
| Biotech Innovation Trends | 60 |
| Competition Landscape | 40 |
| Regulatory Environment (Pharma) | 50 |
| Healthcare Policy & Reimbursement | 40 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 60 |
| Growth | 30 |
| Balance Sheet Health | 55 |
| Cash Flow | 70 |
| Earnings Consistency | 60 |
| Factor | Score |
|---|---|
| Trend Analysis | 25 |
| Momentum | 50 |
| Volume Confirmation | 40 |
| Support & Resistance | 60 |
| Short-Term Oscillators | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
Puma Biotechnology (PBYI) has shown a pattern of positive earnings surprises, with reported EPS exceeding estimates in most of the last several quarters, indicating effective operational management and forecasting.
Low Price-to-Earnings Ratio
The trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio of 4.21 is significantly lower than historical averages and industry peers, suggesting potential undervaluation and a favorable entry point for investors.
Bearish Points (8)
High Price-to-Sales Ratio
The TTM Price-to-Sales (P/S) ratio of 0.9, while not excessively high, warrants consideration given the company's specific market position and growth prospects in the biopharmaceutical sector.
Slowing Revenue Growth Trend
Revenue growth has shown a declining trend from 2021 ($253.16M) to 2024 ($230.47M), indicating potential challenges in expanding market reach or product adoption.
Calendar
August 2025
8
Next Earnings Date
H: $0.07
A: $0.07
L: $0.07
H: 52.00M
A: 52.00M
L: 52.00M
Profile
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Seasonals
Price Target
3.00 USD
The 39 analysts offering 1 year price forecasts for PBYI have a max estimate of 4.00 and a min estimate of 2.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in HER2+ breast cancer with blockbuster drugs like Herceptin, Perjeta, and Kadcyla, which target pathways relevant to PBYI's Nerlynx.
Weight: 90
Strong oncology pipeline, co-developer of Enhertu (trastuzumab deruxtecan), a leading antibody-drug conjugate (ADC) for HER2+ breast cancer, directly competing in PBYI's therapeutic area.
Weight: 88
Developer of Ibrance (palbociclib), a prominent CDK4/6 inhibitor for breast cancer. Recently acquired Seagen, significantly expanding its oncology and ADC capabilities.
Weight: 85
Developer of Verzenio (abemaciclib), a key CDK4/6 inhibitor for breast cancer, indicating a strong focus on similar oncology indications.